April 4, 2022, Tokyo, Japan — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel TrkB agonist peptide which has the equivalent functions to recombinant Brain Derived Neurotropic Factor (BDNF). We will be marketing this product (BDNF alternative) from the beginning of April, 2022. [Read more…]
StemCyte Requests BLA from U.S. FDA for Allogeneic Cord Blood Product
StemCyte, a regenerative cell therapy company, has applied to the U.S. FDA for a BLA for its allogeneic umbilical cord hematopoietic progenitor cell product (HPC-Cord Blood)
StemCyte’s BLA has been accepted for quality review and StemCyte anticipates licensure in 2023
The USPTO Issues a Patent to Cellular Engineering Technologies For Producing Safer Induced Pluripotent Stem Cells
March 24, 2022, Coralville, Iowa — Cellular Engineering Technologies (CET), Inc., an Iowa biotechnology company specializing in cell manufacturing and contract research services, today announced that it has received a patent from the United States Patent and Trademark Office for its virus-free and oncogene-free induced pluripotent stem cell (iPSC) technology. The iPSC technology which was previously published in Future Science Open Access and Regenerative Medicine was developed in collaboration with the John Paul II Medical Research Institute (JP2MRI), a non-profit organization. More recently, the National Institutes of Health awarded CET a SBIR grant to commercialize the technology to provide reproducible iPSC and differentiated neural stem cells that maintain pluripotency and genetic stability during large scale production. [Read more…]
I Peace triples GMP cell manufacturing by expanding CDMO facility
March 7, 2022, Palo Alto, California — I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility. The facility’s expansion, designed to conform to GMP standard, is now almost complete and is expected to start manufacturing cGMP grade cells in April this year after going through a regulatory review and FDA registration update. With this CDMO facility expansion, I Peace will be able to meet the growing needs for GMP iPS cells from pharmaceutical companies and cell therapy developers, and better serve individuals with increased personal iPS cell banking service capacity. [Read more…]
Ciloa secures €5 million for the development of its new generation of biomedicines and vaccines using exosomes
-
The company finalized a €3.5 million fundraising and obtained €1.5 million in public funding as part of the “Emerging Infectious Diseases and CBRN Threats” call for proposals of the France 2030 investment plan, operated on behalf of the French government by Bpifrance. This aid was more specifically granted for the development of a natural vaccine against the Covid-19 delta variant.
-
With its own production unit to meet GMP (Good Manufacturing Practices) standards, Ciloa is now positioned as a major player in the development of therapeutic and preventive products using its tailor-made exosome modification technology.
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 117
- Next Page »